136 related articles for article (PubMed ID: 33121340)
21. Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.
Demarco M; Lorey TS; Fetterman B; Cheung LC; Guido RS; Wentzensen N; Kinney WK; Poitras NE; Befano B; Castle PE; Schiffman M
J Low Genit Tract Dis; 2017 Oct; 21(4):261-267. PubMed ID: 28953116
[TBL] [Abstract][Full Text] [Related]
22. The difference in the effectiveness of human papillomavirus vaccine based on smoking status.
Hikari T; Honda A; Hashiguchi M; Okuma R; Kurihara M; Fukuda A; Okuma E; Nakao Y; Yokoyama M
J Obstet Gynaecol Res; 2022 Jul; 48(7):1859-1866. PubMed ID: 35599387
[TBL] [Abstract][Full Text] [Related]
23. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer.
Castle PE; Fetterman B; Thomas Cox J; Shaber R; Poitras N; Lorey T; Kinney W
Obstet Gynecol; 2010 Jul; 116(1):76-84. PubMed ID: 20567171
[TBL] [Abstract][Full Text] [Related]
24. Impact of a Human Papillomavirus Vaccination Program within Organized Cervical Cancer Screening: Cohort Study.
Martellucci CA; Morettini M; Brotherton JML; Canfell K; Manzoli L; Flacco ME; Palmer M; Rossi PG; Martellucci M; Giacomini G; D'Errico MM; Pasqualini F
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):588-594. PubMed ID: 35027435
[TBL] [Abstract][Full Text] [Related]
25. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.
Larson HJ; Wilson R; Hanley S; Parys A; Paterson P
Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of human papillomavirus vaccination in young Japanese girls: the interim results of the OCEAN study.
Hiramatsu K; Ueda Y; Yagi A; Morimoto A; Egawa-Takata T; Nakagawa S; Kobayashi E; Kimura T; Kimura T; Minekawa R; Hori Y; Sato K; Morii E; Nakayama T; Tanaka Y; Terai Y; Ohmichi M; Ichimura T; Sumi T; Murata H; Okada H; Nakai H; Matsumura N; Mandai M; Saito J; Horikoshi Y; Takagi T; Enomoto T; Shimura K
Hum Vaccin Immunother; 2022 Dec; 18(1):1951098. PubMed ID: 34802371
[TBL] [Abstract][Full Text] [Related]
27. [Economic effectiveness of vaccination against papilloma virus in the Russian Federation].
Kostinov MP; Zverev VV
Zh Mikrobiol Epidemiol Immunobiol; 2012; (2):43-50. PubMed ID: 22693810
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan.
Yagi A; Nakagawa S; Ueda Y; Oka E; Ikeda S; Kakuda M; Kobayashi E; Ito Y; Katayama K; Hirai K; Nakayama T; Kimura T
Cancer Sci; 2024 Mar; 115(3):916-925. PubMed ID: 38158850
[TBL] [Abstract][Full Text] [Related]
29. Pre-vaccination prevalence of infections with 25 non-high-risk human papillomavirus types among 1,000 Slovenian women in cervical cancer screening.
Učakar V; Poljak M; Oštrbenk A; Klavs I
J Med Virol; 2014 Oct; 86(10):1772-9. PubMed ID: 24978445
[TBL] [Abstract][Full Text] [Related]
30. Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology.
Wright TC; Stoler MH; Parvu V; Yanson K; Cooper C; Andrews J
Gynecol Oncol; 2019 Aug; 154(2):360-367. PubMed ID: 31160073
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity.
Kudo R; Sekine M; Yamaguchi M; Hara M; Hanley SJB; Kurosawa M; Adachi S; Ueda Y; Miyagi E; Ikeda S; Yagi A; Enomoto T
Cancer Sci; 2022 Sep; 113(9):3211-3220. PubMed ID: 35730321
[TBL] [Abstract][Full Text] [Related]
32. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
33. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
Herweijer E; Sundström K; Ploner A; Uhnoo I; Sparén P; Arnheim-Dahlström L
Int J Cancer; 2016 Jun; 138(12):2867-74. PubMed ID: 26856527
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology.
Liu AH; Walker J; Gage JC; Gold MA; Zuna R; Dunn ST; Schiffman M; Wentzensen N
Obstet Gynecol; 2017 Dec; 130(6):1218-1225. PubMed ID: 29112672
[TBL] [Abstract][Full Text] [Related]
35. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening.
Song F; Du H; Wang C; Huang X; Qu X; Wei L; Belinson JL; Wu R;
J Med Screen; 2021 Sep; 28(3):318-324. PubMed ID: 32869705
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
[TBL] [Abstract][Full Text] [Related]
37. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers.
Dehlendorff C; Baandrup L; Kjaer SK
J Natl Cancer Inst; 2021 Jul; 113(7):869-874. PubMed ID: 33377930
[TBL] [Abstract][Full Text] [Related]
38. A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation.
Ishimoto T; Yagi A; Nakajima K; Okamoto N; Yukimitsu E; Kawasaki M; Kawae Y; Hayasaka S; Ueda Y; Kimura T
Hum Vaccin Immunother; 2023 Aug; 19(2):2229222. PubMed ID: 37462048
[TBL] [Abstract][Full Text] [Related]
39. Intentions for catch-up HPV vaccination in Japan: an internet survey.
Nakagawa S; Yagi A; Ueda Y; Ikeda S; Kakuda M; Hiramatsu K; Miyoshi A; Kimura T; Hirai K; Sekine M; Nakayama T; Kobayashi E; Miyagi E; Enomoto T; Kimura T
Int J Clin Oncol; 2023 Dec; 28(12):1667-1679. PubMed ID: 37776388
[TBL] [Abstract][Full Text] [Related]
40. Prognosis of high-risk human papillomavirus-related cervical lesions: A hidden Markov model analysis of a single-center cohort in Japan.
Ikesu R; Taguchi A; Hara K; Kawana K; Tsuruga T; Tomio J; Osuga Y
Cancer Med; 2022 Feb; 11(3):664-675. PubMed ID: 34921517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
